GlassScriptPhysician profile
Rajen H Doshi
NPI 1720060536
$17,614.63
in general payments reported to CMS, 2019-2025
33 companies · $1,448 in 2025
The $1,448 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $921 · 2020: $1,842 · 2021: $1,876 · 2022: $2,045 · 2023: $1,615 · 2024: $7,869 · 2025: $1,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,000 · Food and Beverage: $3,943 · Travel and Lodging: $1,988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,000.00 |
| Food and Beverage | $3,942.99 |
| Travel and Lodging | $1,988.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $6,593.23 | 2024 | |
| Teleflex LLC | $3,061.62 | 2021-2025 | Urolift, Barrigel |
| Neotract INC. | $2,174.26 | 2019-2020 | |
| Procept Biorobotics Corporation | $1,777.75 | 2022-2025 | Aquabeam Robotic System, Aquabeam System |
| Calyxo, INC. | $761.89 | 2024-2025 | Cvac Aspiration System |
| Boston Scientific Corporation | $704.79 | 2019-2025 | Greenlight Xps, Rezum Generator, Lithovue |
| Astellas Pharma US INC | $250.89 | 2019-2023 | Myrbetriq |
| Becton, Dickinson and Company | $206.28 | 2024 | Bard Urinary Drainage Bag |
| Urogen Pharma, INC. | $186.82 | 2023-2025 | Jelmyto |
| Cook Medical LLC | $172.61 | 2025 | Cook |
| C. R. Bard, INC. & Subsidiaries | $168.23 | 2024-2025 | Bard Urinary Drainage Bag |
| Janssen Biotech, INC. | $130.96 | 2022-2025 | Erleada, Akeega |
| Laborie Medical Technologies Corp. | $127.92 | 2023-2025 | Optilume Bph Drug Coated Balloon Catheter |
| Progenics Pharmaceuticals, INC. | $122.78 | 2022 | |
| Ferring Pharmaceuticals INC. | $113.88 | 2024-2025 | Adstiladrin |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $111.61 | 2023 | Olympus |
| Convatec INC. | $96.31 | 2022-2025 | |
| Innovation Technologies INC | $94.59 | 2023 | Irrisept |
| Srs Medical Systems, INC. | $92.81 | 2022 | |
| Karl Storz Endoscopy-America | $90.11 | 2019 | |
| Abbvie INC. | $84.39 | 2022-2024 | Lupron Depot |
| Myriad Genetic Laboratories, INC. | $83.03 | 2024-2025 | Prolaris |
| Tolmar, INC. | $79.05 | 2023-2025 | Eligard, Jatenzo |
| Axonics, INC. | $78.70 | 2024 | Axonics, Bulkamid |
| Sumitomo Pharma America, INC. | $73.89 | 2023 | Orgovyx, Gemtesa |
| Medtronic USA, INC. | $37.99 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $36.52 | 2023-2024 | Xiaflex, Aveed |
| Bayer Healthcare Pharmaceuticals INC. | $20.84 | 2025 | |
| Intuitive Surgical, INC. | $20.08 | 2021 | |
| Myovant Sciences INC. | $17.84 | 2022 | |
| 180 Medical, INC. | $16.76 | 2023 | |
| Insmed, INC. | $14.48 | 2021 | |
| Urovant Sciences INC | $11.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajen Doshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.